Who Paid My Doc
Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Eff
Research payments
$4,720,573
Through program year 2025, $4,720,573 in research payments was reported against Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Eff, across 970 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $807,938 | 361 |
| 2024 | Research | $3,554,974 | 516 |
| 2023 | Research | $357,662 | 93 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Huy Nguyen San Jose, CA Named on 101 payments
- Tomohiro Tanaka Iowa City, IA Named on 81 payments
- Eric Chak Los Angeles, CA Named on 70 payments
- Eugene Schiff Miami, FL Named on 61 payments
- Mindie Nguyen Stanford, CA Named on 47 payments
- Kuchikulla Reddy Philadelphia, PA Named on 45 payments
- Glen Lutchman Seattle, WA Named on 43 payments
- Moti Ramgopal Port Saint Lucie, FL Named on 38 payments
- Mark Sulkowski Baltimore, MD Named on 38 payments
- Anita Kohli Flagstaff, AZ Named on 35 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.